Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer

Title: Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
Authors: Sharma, R
Graham, J
Mitchell, H
Brooks, A
Blagden, S
Gabra, H
Item Type: Journal Article
Abstract: There is increasing evidence of the efficacy of dose-dense therapy in the management of platinum-resistant/refractory ovarian cancer. We report our experience of extended weekly carboplatin and paclitaxel in this population group. Twenty patients with platinum-resistant/refractory ovarian cancer received carboplatin AUC 3 and paclitaxel 70 mg m−2 on day 1, 8, 15 q 4 weekly for six planned cycles. Toxicity was assessed using Common Toxicity Criteria. Response was evaluated using radiological and CA125 criteria. Median age was 61 years (range 40–74 years). Median number of prior therapies is three (range 1–8). Response rate was 60% by radiological criteria (RECIST) and 76% by CA125 assessment. Grade 3 toxicities consisted of neutropenia (29% of patients) and anaemia (5%). One patient experienced grade 4 neutropenia. No grade 3/4 thombocytopaenia was reported. Fatigue, nausea and peripheral neuropathy were the most frequent non-hematological side effects. Median progression-free survival was 7.9 months and overall survival was 13.3 months. The dynamics of response to dose-dense therapy were as rapid as with front-line therapy within the same patient. This dose-dense regimen can be extended to at least 18 weekly cycles over 6 months and is well tolerated with high response rates in heavily pre-treated, platinum-resistant ovarian cancer. It forms a highly active and tolerable cytotoxic scaffold to which molecular-targeted therapies can be added in platinum-resistant ovarian cancer.
Issue Date: 17-Feb-2009
Date of Acceptance: 11-Jan-2009
URI: http://hdl.handle.net/10044/1/71743
DOI: https://doi.org/10.1038/sj.bjc.6604914
ISSN: 0007-0920
Publisher: Springer Nature
Start Page: 707
End Page: 712
Journal / Book Title: British Journal of Cancer
Volume: 100
Issue: 5
Copyright Statement: © 2009 The Authors and Springer. From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
ovarian cancer
resistance
relapse
carboplatin
paclitaxel
weekly
PEGYLATED LIPOSOMAL DOXORUBICIN
RANDOMIZED PHASE-III
LONG-TERM SURVIVAL
CA-125 HALF-LIFE
PERITONEAL CARCINOMA
PROGNOSTIC VALUE
SOLID TUMORS
PACLITAXEL
CARBOPLATIN
TRIAL
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
CA-125 Antigen
Carboplatin
Drug Administration Schedule
Drug Resistance, Neoplasm
Feasibility Studies
Female
Humans
Middle Aged
Ovarian Neoplasms
Paclitaxel
Platinum Compounds
Recurrence
Retrospective Studies
Treatment Outcome
Humans
Ovarian Neoplasms
Recurrence
Platinum Compounds
Paclitaxel
Carboplatin
Antineoplastic Combined Chemotherapy Protocols
CA-125 Antigen
Treatment Outcome
Drug Administration Schedule
Retrospective Studies
Feasibility Studies
Drug Resistance, Neoplasm
Adult
Aged
Middle Aged
Female
Science & Technology
Life Sciences & Biomedicine
Oncology
ovarian cancer
resistance
relapse
carboplatin
paclitaxel
weekly
PEGYLATED LIPOSOMAL DOXORUBICIN
RANDOMIZED PHASE-III
LONG-TERM SURVIVAL
CA-125 HALF-LIFE
PERITONEAL CARCINOMA
PROGNOSTIC VALUE
SOLID TUMORS
PACLITAXEL
CARBOPLATIN
TRIAL
1112 Oncology and Carcinogenesis
Oncology & Carcinogenesis
Publication Status: Published
Online Publication Date: 2009-02-17
Appears in Collections:Division of Surgery
Division of Cancer



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons